Dec 31, 2021

Penumbra Q4 2021 Earnings Report

Reported financial results for the fourth quarter and full year ended December 31, 2021.

Key Takeaways

Penumbra, Inc. reported a revenue of $204.0 million for the fourth quarter of 2021, representing a 22.2% increase compared to the fourth quarter of 2020. The company's gross profit for the quarter was $125.4 million, or 61.5% of total revenue.

Total revenue increased to $204.0 million for the fourth quarter of 2021, up 22.2% compared to Q4 2020.

US revenue for Q4 2021 was $144.5 million, a 23.7% increase year-over-year.

Revenue from vascular products grew to $113.6 million, a 30.4% increase, while neuro products grew to $90.4 million, a 13.3% increase.

Gross profit for Q4 2021 was $125.4 million, or 61.5% of total revenue, impacted by higher labor and logistics costs.

Total Revenue
$204M
Previous year: $167M
+22.2%
EPS
$0.1
Previous year: $0.42
-76.2%
Gross Margin
61.5%
Previous year: 56.5%
+8.8%
Gross Profit
$125M
Previous year: $94.3M
+33.0%
Cash and Equivalents
$59.4M
Previous year: $69.7M
-14.8%
Free Cash Flow
-$17.4M
Previous year: -$5.84M
+197.5%
Total Assets
$1.24B
Previous year: $823M
+51.2%

Penumbra

Penumbra

Penumbra Revenue by Segment

Penumbra Revenue by Geographic Location

Forward Guidance

Penumbra projects total revenue for 2022 to be in the range of $860 million to $875 million, which represents growth of 15% to 17% over 2021 revenue of $747.6 million.

Revenue & Expenses

Visualization of income flow from segment revenue to net income